Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA - Parent Project Muscular Dystrophy
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy :: Capricor Therapeutics, Inc. (CAPR)
Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet
Duchenne Muscular Dystrophy Cell Therapy CAP-1002 Demonstrates Improvements in LVEF
Hi-CV Cap 1002 TDK | Mouser
CAP-1002 - Parent Project Muscular Dystrophy
Amazon.com: Fuel Gloss Black Center Cap 1002-50GB Cap M-776 : Automotive
Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial | Neurology